氢溴酸普拉格雷醋酸合物的抗血栓作用研究

详细信息    查看全文 | 推荐本文 |

英文篇名：Study on Antithrombotic Effects of Prasugrel Hydrobromide Acetic Acid Compound 作者：郑晓霞 ; 程艳玲 ; 刘纯 ; 黄艳妮 英文作者：ZHENG Xiaoxia;CHENG Yanling;LIU Chun;HUANG Yanni;Shandong Academy of Pharmaceutical Sciences/Shandong Provincial Key Lab of Chemical Drugs; 关键词：氢溴酸普拉格雷醋酸合物 ; 盐酸普拉格雷 ; 硫酸氢氯吡格雷 ; 抗血栓 ; 抗血小板聚集 ; 体外 ; 体内 英文关键词：Prasugrel hydrobromide acetic acid compound;;Prasugrel hydrochloride;;Clopidogrel bisulfate;;Antithrombus;;Antiplatelet aggregation;;in vitro;;in vivo 中文刊名：ZGYA 英文刊名：China Pharmacy 机构：山东省药学科学院/山东省化学药物重点实验室; 出版日期：2018-11-30 出版单位：中国药房 年：2018 期：v.29;No.640 基金：山东省科学技术厅中央引导地方科技发展专项资金项目 语种：中文; 页：ZGYA201822016 页数：4 CN：22 ISSN：50-1055/R 分类号：79-82

摘要

目的:探讨氢溴酸普拉格雷醋酸合物的抗血栓作用及其可能机制。方法:以硫酸氢氯吡格雷为阳性对照,采用全自动血栓检测仪测定低、中、高剂量氢溴酸普拉格雷醋酸合物和盐酸普拉格雷(均为0.05、0.5、5 mg/kg,以普拉格雷计)作用后大鼠体外血栓长度、湿质量和干质量,采用酶联免疫吸附测定法检测低、中、高剂量氢溴酸普拉格雷醋酸合物(0.05、0.5、5 mg/kg,以普拉格雷计)作用后大鼠血小板中环磷酸腺苷(cAMP)的含量;用角叉菜胶诱发小鼠体内血栓形成,以游标卡尺测量低、中、高剂量氢溴酸普拉格雷醋酸合物和盐酸普拉格雷(均为0.2、2、20 mg/kg,以普拉格雷计)预处理后小鼠的黑尾长度及相对平均长度。结果:经中、高剂量氢溴酸普拉格雷醋酸合物和盐酸普拉格雷作用后,大鼠体外血栓长度均较正常对照组显著缩短,血栓湿质量和干质量均较正常对照组显著减轻(P<0.05或P<0.01);氢溴酸普拉格雷醋酸合物各剂量组大鼠上述指标与盐酸普拉格雷同等剂量组、氢溴酸普拉格雷醋酸合物高剂量组大鼠上述指标与硫酸氢氯吡格雷组比较,差异均无统计学意义(P>0.05)。经中、高剂量氢溴酸普拉格雷醋酸合物作用后,大鼠血小板中cAMP的含量均较正常对照组显著升高(P<0.05或P<0.01)。经中、高剂量氢溴酸普拉格雷醋酸合物和盐酸普拉格雷预处理后,小鼠的黑尾长度及相对平均长度均较模型组显著缩短(P<0.01),且氢溴酸普拉格雷醋酸合物高剂量组和盐酸普拉格雷高剂量组小鼠上述指标均显著短于硫酸氢氯吡格雷组(P<0.05);而氢溴酸普拉格雷醋酸合物各剂量组小鼠上述指标与盐酸普拉格雷同等剂量组比较,差异均无统计学意义(P>0.05)。结论:氢溴酸普拉格雷醋酸合物可显著缩短大鼠体外血栓长度,减轻血栓湿质量和干质量,缩短角叉菜胶致小鼠的黑尾长度及相对平均长度,且其作用与盐酸普拉格雷相当。上述作用可能与氢溴酸普拉格雷醋酸合物上调血小板中cAMP的含量有关。
        OBJECTIVE: To investigate the antithrombotic effects of prasugrel hydrobromide acetic acid compound.MEHTODS:Using clopidogrel bisulfate as positive control,automatic thrombus detector was used to detect length,wet weight and dry weight of in vitro thrombus in rats after treated with low-dose,medium-dose and high-dose of prasugrel hydrobromide acetic acid compound and prasugrel hydrochloride(0.05,0.5,5 mg/kg,by prasugrel). The content of c AMP in platelet of rats was determined by ELISA after treated with low-dose,medium-dose and high-dose of prasugrel hydrobromide acetic acid compound(0.05,0.5,5 mg/kg,by prasugrel). The in vivo thrombus in mice was induced by carrageenan. The black tail length and the relative length were measured with vernier calipers after pre-treated with low-dose,medium-dose and high-dose of prasugrel hydrobromide acetic acid compound and prasugrel hydrochloride(0.2,2,20 mg/kg,by prasugrel). RESULTS:After treated with medium-dose and high-dose of prasugrel hydrobromide acetic acid compound and prasugrel hydrochloride,the length of in vitro thrombus was shortened significantly,wet weight and dry weight were decreased significantly,compared with normal control group(P<0.05 or P<0.01). There was no statistical significance in above indexes between prasugrel hydrobromide acetic acid compound groups and corresponding prasugrel hydrochloride groups, between prasugrel hydrobromide acetic acid compound high-dose group and clopidogrel bisulfate groups(P>0.05). After treated with medium-dose and high-dose of prasugrel hydrobromide acetic acid compound,the content of cAMP in platelet of rats was increased significantly,compared with normal control group(P<0.05 or P<0.01). After pretreated with medium-dose and high-dose of prasugrel hydrobromide acetic acid compound and prasugrel hydrochlorde,black tail length and the relative length were shortened significantly,compared with model group(P<0.01),and above indexes of prasugrel hydrobromide acetic acid compound high-dose group and prasugrel hydrochloride high-dose group were significantly shorter than clopidogrel bisulfate group(P<0.05). There was no statistical significance in above indexes between prasugrel hydrobromide acetic acid compound groups and corresponding prasugrel hydrochloride groups(P>0.05). CONCLUSIONS:Prasugrel hydrobromide acetic acid compound can significantly decrease the length,wet weight and dry weight of in vitro thrombus,and shorten the black tail length and the relative length of mice. Prasugrel hydrobromide acetic acid compound and prasugrel hydrochloride have similar antithrombotic effects. The above effects are performed by up-regulating the content of cAMP in platelet with prasugrel hydrobromide acetic acid compound.

引文

[1]荆亚萍,申东升,熊维,等.新一代血小板抑制剂:普拉格雷[J].国际药学研究杂志,2008,35(5):373-376.
    [2]孙忠实,朱珠.第三代抗血小板药普拉格雷[J].中国新药杂志,2010,19(22):2023-2025.
    [3]韩聪凡,冯文化.血栓性疾病抗血小板聚集药物研究进展[J].中国新药杂志,2016,25(12):1363-1369.
    [4]姚懿,袁晋青.新型抗血小板药物普拉格雷、替格瑞洛与氯吡格雷的临床对比研究进展[J/CD].中华临床医师杂志:电子版,2013,7(19):8870-8873.
    [5]王巍巍,王焕群,李凤新,等.K-01对血小板聚集与血栓形成的抑制作用[J].中国新药杂志,2015,24(24):2873-2877.
    [6]余志华,文晓柯,吴雅莉.冠心舒胶囊对大鼠体外血栓形成的影响[J].医学临床研究,2015,32(12):2478-2479.
    [7]苏丙凡,张智慧,商亚珍.灯盏花素抑制角叉菜胶诱导小鼠血栓形成[J].承德医学院学报,2009,26(1):8-9.
    [8]何国林,周卫军,王羚郦,等.蒲黄的抗血栓有效部位筛选[J].中国实验方剂学杂志,2014,20(10):138-141.
    [9]戴淑芳,邹向阳,李华,等.重组水蛭素对角叉菜胶对小鼠尾部血栓的抗凝效应分析[J].中国误诊学杂志,2010,10(25):6081-6082.
    [10]张小梅,李炎坤.通脉对治疗血瘀证的抗血小板聚集和体外血栓作用的研究[J].安徽医药,2016,20(8):1455-1457.
    [11]王二辉,刘莹.血小板P2Y12受体拮抗剂临床研究概况[J].中国医学创新,2010,7(29):194-196.
    [12]杨宏艳,王晓良.抗血小板药物研究进展[J].中国药学杂志,2012,47(4):250-254.
    [13]李华,申瑶.口服抗血小板药物治疗冠心病的疗效观察[J].临床医药文献杂志,2016,3(6):1121-1122.
    [14]SUGIDACHI A,OGAWA T,KURIHARA A,et al.The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite[J].J Thromb Haemost,2007,5(7):1545-1551.
    [15]WALIENTIN L,VARENHORST C,JAMES S,et al.Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease[J].Eur Heart J,2008,29(1):21-30.
    [16]李贤峰,王兆君.新型抗血小板药普拉格雷在冠心病应用中的研究进展[J].临床军医杂志,2009,37(1):125-126.